Sergio Traversa, CEO at Relmada Therapeutics, Inc., Buys Shares Worth $828,000

Relmada Therapeutics, Inc. (RLMD) disclosed that Sergio Traversa, who holds the position of CEO at the company, was involved in buying 200,000 shares, per a Form 4 filing with the SEC.

The transaction was executed at a price of $4.14 per share, for a total value of approximately $828,000.

Company insiders are required to disclose changes in their stock ownership to the SEC on Form 4, typically within two business days of the trade.

Insider buying is sometimes viewed by investors as a signal of confidence in a company's prospects, though a single transaction does not necessarily indicate a broader trend.